Mitophagy in Alzheimer's disease: Molecular defects and therapeutic approaches

Mol Psychiatry. 2023 Jan;28(1):202-216. doi: 10.1038/s41380-022-01631-6. Epub 2022 Jun 3.

Abstract

Mitochondrial dysfunctions are central players in Alzheimer's disease (AD). In addition, impairments in mitophagy, the process of selective mitochondrial degradation by autophagy leading to a gradual accumulation of defective mitochondria, have also been reported to occur in AD. We provide an updated overview of the recent discoveries and advancements on mitophagic molecular dysfunctions in AD-derived fluids and cells as well as in AD brains. We discuss studies using AD cellular and animal models that have unraveled the contribution of relevant AD-related proteins (Tau, Aβ, APP-derived fragments and APOE) in mitophagy failure. In accordance with the important role of impaired mitophagy in AD, we report on various therapeutic strategies aiming at stimulating mitophagy in AD and we summarize the benefits of these potential therapeutic strategies in human clinical trials.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease* / metabolism
  • Amyloid beta-Peptides / metabolism
  • Animals
  • Autophagy / genetics
  • Disease Models, Animal
  • Humans
  • Mitochondria / metabolism
  • Mitophagy / physiology

Substances

  • Amyloid beta-Peptides